

CONFLICT OF INTEREST

RESEARCH GRANTS -TO UNIVERSITY
 – Dusa, Valeant, Viamet

 Amgen, Abbvie, Boehringer Ingelheim, Celgene, Lilly, Merck, Novartis, Pfizer

CONSULTANT- HONORARIUM

– Anacor, Celgene, Lilly, Pfizer, Sun, Valeant

OBJECTIVES

- Review NEW DEVELOPMENTS in the treatment of select cutaneous fungal infections
 - Malassezia:
 Pityriasis (tinea) versicolor, Malassezia folliculitis, seb derm
 - Candidiasis
- Update on treatment of onychomycosis including older
- oral antifungal drugs and newer topical agents
 What to do with laboratory monitoring?

ANTIFUNGAL THERAPEUTICS 101

- Azole Family
- Ketoconazole
- Itraconazol
- Voriconazole
- (VT-1161)
- Allylamine far
- terbinafine
- Griseofulvin
- Azole Family

 Activity against yeasts, Candida, dermatophytes and non dermatophytes

 Allylamines and
 - Allylamines and Griseofulvin

 Anti-dermatophyte





Pityriasis (tinea) Versicolor

- Fluconazole 200 mg daily for 5-7 days
- Flu 300 mg once weekly for 2 weeks (98% cure rate)
- Itraconazole 200 mg daily for 5 days (100% cure rate)
- Oral terbinafine and griseofulvin are not effective
- Topical ketoconazole 2% shampoo and cream daily for 2 weeks

Bolognia textboo

Ketoconazole has best MICs for Malassezia

KETOCONAZOLE TABLETS

- July 2013 FDA withdrew indications for ketoconazole tablets
- Drug is still available, but no longer indicated for cutaneous fungal infections
- Does not effect ketoconazole cream or shampoo
- Substitute with another azole antifungal drug

KETOCONAZOLE TABLETS

- European Medicines Agency (CHMP) suspended usage of drug due to the conclusion that risk of liver injury is greater than benefit of antifungal treatment. July 2013
- Triggered by French authorities suspending the drug after a 2 year review

KETOCONAZOLE TABLETS









Fatty Substance	Growth of <i>M. furfur</i>
	e
Corn oil	
Coconut oil	
Oleic acid	
	++





PITYROSPORUM FOLLICULITIS

- Differential diagnosis of acne
- Acneiform pruritic monomorphic pustules on upper back and chest, occasionally face
- Diagnosis confirmed by skin biopsy showing organism in yeast state below level of epidermis

Malassezia Folliculitis



Itraconazole 200 mg daily for 2 weeks – is lipophilic

- Fluconazole 200 mg daily for 2 weeks- not lipophilic
- Avoid oils to skin









CANDIDA PARONYCHIA

- Fluconazole 200 mg daily for 5 days then once weekly for 8 weeks (or until clear)
- Topical antifungal cream
 - Ciclopirox, ketoconazole or other azole cream
- Avoid cuticle manipulation to prevent recurrence

AVOID KETOCONAZOLE TABLETS





CURRENT TREATMENT OF ONYCHOMYCOSIS					
ORAL DRUGS Terbinafine Itraconazole Fluconazole* 	TOPICAL DRUGS - 10% efinaconazole solution - 5% tavaborole solution - 8% ciclopirox lacquer				
*not FDA approved	ORAL NEW DEVELOPMENTS VT-1161				



TOPICAL ONYCHOMYCOSIS TREATMENT

- SOLUTIONS:
- Efinaconazole10%
- Non-lacquer alcohol based therapies can be delivered on, under and around the nail bed









































	PI	HASE 3 CLI	NICAL STUDIES	
	COMPLETE C	URE	MYCOLOGIC CURE	
	Terbinafine	38%	70%	a succession
200	Itraconazole	14%	54%	
all and all all all all all all all all all al	Meltrex itra	22%	44%	
	Fluconazole	37-48%*	47%-62%*	
	NC	OT ALL PATIE	ENTS ARE CURED	
-		Data Per Pa	ckage label*	
	** Fluconazole not FDA approved for onychomycosis		Complete cure= normal nail, myc cure	

VT-110	51
Next-generation oral antifungal	TETRAZOLE
Very high penetration into nail	
Favorable oral PK profile; once-	
weekly dosing	A B B B B B B B B B B B B B B B B B B B
Robust safety profile to date	
EXCELLENT results thus far in	Nevel "Tetrazola" Metal
phase 2 onychomycosis study	Binding Group

VT-1161 IS A CYP51 INHIBITOR

- Novel potent inhibitor of fungal lanosterol demethylase (CYP51) and binds more tightly to fungal CYP51 than human CYP51
- Less potential for drug interaction than azoles due to less inhibition of P450 enzymes
- Broad spectrum activity- dermatophytes, Candida and molds









Onychomycosis: Fill in the Gaps

- VT-1161 Has activity against dermatophytes, Candida and molds and is more potent than itraconazole
- Intermittent dosing similar to fluconazole
- Phase 3 study coming soon
- Likely to offer a viable option to patients with onychomycosis, particularly those who failed or did not respond to oral terbinafine.

What About Diagnosis? Is There a Gap?

- Empiric treatment with terbinafine for patients with suspected onychomycosis is more cost effective than confirmatory testing with minimal effect on safety
- Confirmatory testing before efinaconazole will reduce costs across a range of disease prevalence

TREAT EMPIRICALLY WITH ORAL TERBINAFINE

Mikailov A et al JAMA Derm 2015 online Dec 23

Laboratory Monitoring

- Hepatic risk for Terbinafine: 1:50K to 120K
- Trend away from routine monitoring
 - Isotretinoin
 - Spironolactone
 - Terbinafine

Laboratory Monitoring

- Baseline hepatic panel and CBC for terbinafine, itraconazole and fluconazole: is this needed?
 - Trend is away from routine monitoring
 - Liver injury is very rare
 - Most common cause of drug induced hepatitis is trimethoprim-sulfamethoxazole
 - Pulse dosing likely safer- alcohol analogy

Kanzler MK JAMA Derm 2015 online Dec 23

KEY POINTS

- Oral ketoconazole should not be used at all!
- Avoid topical oils in patient with Malassezia
- Topical efinaconazole and tavaborole are effective VT-1161 is an oral tetrazole antifungal with
- excellent potential in onychomycosis
- Empiric oral terbinafine is cost effective
- Side effects can occur so choose your treatment with care

